Join the Oncology Voice Network. Join for Free
The MSL Role - Big Pharma Vs. Small Biotech
MSL role differences large pharma vs small biotech career advice for MSLs MSL job market 2024 cultural differences in pharma

The MSL Role - Big Pharma Vs. Small Biotech


Share This Article


Summary

In this episode, Sarah Ussery joins to discuss her career journey and the distinctions between working in big pharma versus small biotech companies. Sarah provides an overview of both environments, highlighting the evolution of the MSL role and the responsibilities unique to each. She explores growth opportunities and the job market for both sectors, while addressing the challenges and cultural differences encountered in each setting. The conversation includes advice for MSLs navigating their careers in 2024, with insights on resume building and choosing between large pharma and small biotech. The episode concludes with closing remarks and a call to action.

My guest today is Sarah Ussery, Medical Affairs Leader who discusses the differences in MSL function between large pharma and small biotech.

  Sarah shares….

👉 What is considered Large Pharma VS Small Biotech
👉 How do MSL responsibilities differ by size of company
👉 How are MSLs evaluated differently by different companies
👉 How do the frustrations differ for MSLs in different size companies
👉 What are the cultural differences between different size companies

Click for Source
MSL role differences, large pharma vs small biotech, career advice for MSLs, MSL job market 2024, cultural differences in pharma

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Where Did My Interview Go Wrong?
Partner Avatar Tom Caravela

Where Did My Interview Go Wrong?

Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Explore OVN